Abacavir & Lamivudine (Epzicom)
|
|
Systemic anti-infective
|
|
Antiretroviral agent
|
|
HIV-1 infection
|
|
1. Adults:>18yrs: 1 tab daily. Hepatic or renal impairment (CrCl<50mL/min): not recommended.
2. Children:18yrs: not recommended.
|
|
Category C
|
|
Hypersensitivity reactions (may be fatal), sleep or depressive disorders, headache, fatigue, malaise, dizziness, GI upset, fever, headache, rash (may be severe, eg, Stevens-Johnson), anorexia, neuropathy, anxiety, respiratory effects, musculoskeletal pain, mild hyperglycemia, elevated triglycerides, anemia, neutropenia, immune reconstitution syndrome, fat redistribution, lactic acidosis, severe hepatomegaly with steatosis, abnormal liver function tests, pancreatitis.
|
Pregnancy Risk Categories defined:
A: Studies in pregnant women failed to show a risk to the fetus in the first
trimester - with no evidence of risk in the later trimesters.
B: Animals studies indicate no adverse effect to the fetus, but there are no adequate,
clinical studies in pregnant women.
C: Animal studies have shown an adverse effect on the fetus, but there are no adequate,
clinical studies in humans. Despite potential risks, the drug may be useful in pregnant
women.
D: There is evidence of risk to the human fetus, but the potential benefits of use in
pregnant women may be acceptable, despite potential risks.
X: Studies in animals or humans show fetal abnormalities, or adverse reaction reports
indicate evidence of fetal risk. Warning: the risks involved clearly outweigh any
potential benefit from using the drug in pregnant women, regardless of trimester.
NR: Not rated (i.e., no information available at this time as to the potential
risks or benefits).
|
|
|
|